Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Opdivo (nivolumab) in combination with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in patients with tumour cell PD-L1 expression ≥1%.
This recommendation was based on Phase 3 CheckMate -816 trial results, showing improved event-free survival and pathologic complete response compared to chemotherapy alone when given before surgery.
If approved, Opdivo with chemotherapy would be the first neoadjuvant immunotherapy-based option for NSCLC patients in the European Union.
The CHMP recommendation will now be reviewed by the European Commission.
Opdivo has already been approved for neoadjuvant treatment of resectable NSCLC in multiple countries, including the United States, Japan and China. Opdivo-based treatments have demonstrated efficacy in neoadjuvant or adjuvant treatment of lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation